Compare Expeditors International of Wshngtn Inc (EXPD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Natera Inc. Common Stock — how do they compare? Expeditors International of Wshngtn Inc trades at $197.41 (market cap $25.37B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.2× Expeditors International of Wshngtn Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.83% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Natera Inc. Common Stock for 0 Days on average.
| EXPD | NTRA | |
|---|---|---|
Market Cap | $25.37B | $57.03B |
Volume | 1,236,812 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $196.38 | $425.64 |
52-Week Low | $117.35 | $179.42 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $24.90B | $56.18B |
Dividend Yield | 0.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $196.38, up 1.54% today, with a bullish technical signal from moving averages and strong profitability metrics including a 42.6% ROE. Recent quarters show consistent earnings beats, and cash flow improved to a positive $166 million in 2025. News highlights efficiency initiatives and AI's impact on freight markets, supporting positive momentum.
The stock's outlook is mixed; fundamentals are solid with revenue growth to $12.0B projected for 2026, but valuation is elevated at a P/E of 28.4, and analyst consensus is cautious with a $179.43 price target below current levels. Risks include reliance on freight demand cycles and competitive pressures in logistics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
